Netherlands
· Delayed Price · Currency is EUR BenevolentAI Company Description
BenevolentAI S.A. operates as a clinical-stage artificial intelligence (AI) enabled drug discovery and development company.
Its Benevolent platform integrates AI and science to uncover and develop drugs for complex diseases. The company’s development pipeline includes BEN-8744, an oral phosphodiesterase 10 (PDE10) inhibitor under phase 1 study for the treatment of Ulcerative Colitis; BEN-28010, an oral brain penetrant CHK1 inhibitor under preclinical study for the treatment of Glioblastoma Multiforme; BEN-34712, a preclinical candidate for the potential treatment of ALS; and various candidates for the treatment of fibrosis and Parkinson’s disease.
It has collaboration agreements with AstraZeneca and Merck to enhance understanding of complex disease biology and identify new targets.
The company was founded in 2013 and is headquartered in London, United Kingdom.
| Country | Luxembourg |
| Founded | 2013 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 248 |
| CEO | Joerg Moeller |
Contact Details
Address: 4-8 Maple Street London, W1T 5HD United Kingdom | |
| Phone | 44 20 3781 9360 |
| Website | benevolent.com |
Stock Details
| Ticker Symbol | BAI |
| Exchange | Euronext Amsterdam |
| Fiscal Year | January - December |
| Reporting Currency | GBP |
| ISIN Number | LU2355630455 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Kenneth Mulvany | Executive Chairman |
| Dr. Ivan Griffin Ph.D. | Co-Founder and Chief Business Officer |
| Michael Brennan | Co-Founder, Chief Financial Officer, Chief Strategy Officer and Executive Director |
| Dr. James Malone | Chief Technology Officer |
| Dr. Anne Phelan | Chief Scientific Officer and Site Head for the Benevolent Cambridge Laboratories |
| Fleur Wood | Vice President of Investor Relations |
| Will Scrimshaw | General Counsel and Company Secretary |
| Anna Fullerton-Batten | Chief People Officer |
| Christina Busmalis | Chief Revenue Officer |